Because the model was voluntary for Part D plan sponsors, CMS designed financial incentives to encourage plan participation
The clinical evidence base for GLP-1 therapy keeps expanding into new indication categories cardiovascular risk reduction, potential Alzheimer's benefit, heart failure management, sleep apnea, and kidney disease protection are all active investigation areas
There is no absolute contraindication to using GLP-1 receptor agonists in patients with Hashimoto's disease or established hypothyroidism
If these are your primary side effects, evening injection can actually make things worse because lying down after injection is the worst position for reflux
Omzo's weight-loss page states that "many members see up to 25% body weight reduction over time" - with the key qualifiers being "many" (not all), "up to 25%" (a ceiling, not an average), and "over time" (no specific timeframe defined)
How damaging is it for stars like Kourtney Kardashian to promote weight loss supplements